ExpreS2ion appoints new Chief Medical Officer

Hørsholm, Denmark, December 21, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby announces the appointment of Dr. Mattis F. Ranthe as the Company’s new Chief Medical Officer (CMO). Dr. Ranthe brings a decade of broad clinical experience, and he will be responsible for ensuring the progression of ExpreS2ion’s development pipeline activities, including clinical safety and efficacy trials. Dr. Ranthe will begin his employment on February 1, 2022 at ExpreS2ion’s headquarters in Hørsholm, Denmark.

Dr. Mattis F. Ranthe will take over the responsibility for the Company’s development pipeline activities from Dr. Lars J. Petersen, who will step down from his position as part-time Medical Director, Oncology, in light of the new CMO role. At ExpreS²ion, the Company’s medical activities will continue to be supported by drug development consultants within oncology, which will now be under Mattis’ leadership.

Furthermore, considering ExpreS²ion’s increased strategic focus on research and development and clinical planning/management, Mr. Eske Rygaard-Hjalsted is resigning from the position as Vice President, Business Development.

These organizational changes are made to facilitate the further advancement of the Company’s pipeline development projects, with clinical trials planned within the next 1-2 years for COVID-19, breast cancer, influenza and malaria.

ExpreS²ion’s CEO Bent Frandsen comments: 
“It is with great pleasure that I welcome Mattis to the ExpreS²ion team as our new CMO. I feel confident that his skillset and experience will ensure a further professionalisation of our development pipeline’s clinical activities.”

Short biography of the new amendment to the management team

Dr. Mattis Flyvholm Ranthe, Chief Medical Officer

Dr. Mattis F. Ranthe holds a PhD in Cardiovascular Epidemiology (2013), and a Medical Diploma (MD) (2006) from the University of Copenhagen, Denmark. Mattis’ background as a physician with a broad clinical experience, research in academia, positions in various pharmaceutical companies (including Novo Nordisk, ALK, and GSK Vaccines), and extensive taught courses in drug development makes him perfectly suited to design and lead successful clinical development programs for ExpreS²ion.

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se
 

This press release constitutes inside information that ExpreS2ion Biotech Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company’s news distributor, Cision, at the publication of this press release.

For further information about ExpreS²ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion has developed a unique technology platform, ExpreS², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS²ion develops novel VLP based vaccines through its 34%-owned joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com.

Tags: